News !

9th of January 2017

We are delighted to welcome Dr Julien Delobel PhD to our laboratory. Julien is coming to us from Berlin and will be a SNSF Post-doctoral researcher in the lab working with Dr Raffaele Renella MD PhD on the cellular surfaceome of healthy and Sickle Cell Disease erythropoiesis.

 

10th of October 2016

A new manuscript by the lab has just been published in BMC Cancer investigating the role of Aldehyde Dehydrogenase (ALDH) in the aggressive phenotype of neuroblastoma! Interestingly, the enzymatic activity of ALDH plays a role in the aggressive properties and the 4-hydroxycyclophosphamide resistance of NB, and our team shows ALDH1A3 isoenzyme activity increases the aggressive capacities of a subset of NB cells. Congratulations to all of the co-authors for this great achievement and contribution.

Flahaut M, Jauquier N, Chevalier N, Nardou K, Balmas Bourloud K, Joseph JM, Barras D, Widmann C, Gross N, Renella R, Mühlethaler-Mottet A. Aldehyde dehydrogenase activity plays a key role in the aggressive phenotype of neuroblastoma. BMC Cancer.

 

9th of September 2016

We are very excited to have a new job opening for a postdoctoral research fellow !!!! See here for details.

 

6th of September 2016

jciA paper by Drs Brendel, Guda, Renella and others under the leadership of Prof David A Williams (Boston Children’s Hospital, Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA) reporting of a pre-clinical gene therapy study for sickle cell disease has been published in the Journal of Clinical Investigation today! In this paper, work initiated by Drs Renella and Milsom in the Williams Laboratory in 2011 has paved the way for a novel gene therapy approach for sickle cell disease, aiming at inducing the expression of fatal haemoglobin (HbF) by knocking down BCL11A, a protein involved in the haemoglobin switch. For more details and explanations please see the Harvard Medical School Gazette article and the STAT website article covering this publication.

Brendel C, Guda S, Renella R, Bauer DE, Canver MC, Kim YJ, Heeney MM, Klatt D, Fogel J, Milsom MD, Orkin SH, Gregory RI, Williams DA. Lineage-specific BCL11A knockdown circumvents toxicities and reverses sickle phenotype. J Clin Invest. 2016

 

14th of July 2016

maxresdefaultA paper by Dr Philip Altrock (Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA) and colleagues, with the contribution of Dr Raffaele Renella, has been published early online in the American Journal of Hematology this week. It explores an integrative theoretical and experimental approach, which has identified the target frequency of HSC alterations required for effective treatment of sickling syndromes in humans. This work replaces episodic observations of such target frequencies with a mathematical modeling framework that covers a large and continuous spectrum of chimerism conditions. [Altrock PM, Brendel C, Renella R, Orkin SH, Williams DA, Michor F. Mathematical modeling of erythrocyte chimerism informs genetic intervention strategies for sickle cell disease. Am J Hematol. 2016]

 

18th of May 2016

cover proteomicsA paper by Dr Raffaele Renella has been published early online in Proteomics – Clinical Applications this week, reviewing the challenges and opportunities of studying Sickle Cell Disease with proteomic approaches [Renella R. Clinically-oriented proteomic investigation of sickle cell disease: Opportunities and challenges. Proteomics Clin Appl. 2016.]

 

 

30th March 2016

ANR-2016-Draft-1Dr Annick Mühlethaler-Mottet has been invited to give an oral as well as two poster presentations at the Advances in Neuroblastoma Research Meeting (ANR 2016) in Cairns (Australia) in June. Congratulations for this achievement!

 

 

1st February 2016

We are delighted to welcome Lucie Vivancos MSc to our laboratory. Lucie is coming to us from the University of Marseille and will be a PhD candidate in the lab working with Dr Annick Mühlethaler on the role of ALK mutations in the pathogenesis of neuroblastoma.